AstraZeneca reports higher Q2 revenue and reiterates 2030 target after trial setback
Core EPS and revenue beat forecasts as oncology and rare disease sales offset Farxiga generic pressure, while AstraZeneca maintained its $80 billion revenue ambition despite recent late-stage trial setbacks.
AstraZeneca reported stronger-than-expected second-quarter 2026 results, with total revenue rising to $15.38 billion and core earnings per share reaching $2.63, ahead of analyst forecasts. Growth in Oncology and Rare Disease, including demand for Enhertu and Imfinzi, helped offset generic pressure on Farxiga after the diabetes drug lost U.S. exclusivity. The company reiterated its outlook for mid-to-high single-digit revenue growth and low double-digit core EPS growth, and Chief Executive Officer Pascal Soriot said AstraZeneca remains on track for its $80 billion total revenue ambition despite disappointment over the CARDIO-TTRansform Phase III trial. In a separate pipeline update, AstraZeneca reported mixed Phase III results for Ultomiris in HSCT-TMA and said it is proceeding with regulatory filings for pediatric use while continuing discussions with regulators on the broader program.
- Phase III trial: A late-stage clinical study that tests a treatment in a larger patient group to confirm effectiveness and monitor safety.
- primary endpoint: The main outcome a clinical trial is designed to measure to determine whether a treatment worked.
- orphan drug designation: A regulatory status intended to encourage development of treatments for rare diseases, often by offering incentives such as market exclusivity.